BioSpace News Archive

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at several upcoming virtual investor events in August and September as follows: BTIG Virtual Biotechnology Conference: August 10 th – 11 th A BTIG analyst will host a fireside chat with Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, to discuss the Com

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, announced financial results for the second quarter ended June 30, 2020 and provided a business update.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday August 10, 2020 at 8:30 AM ET to discuss results for the second quarter of 2020 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.

DaVita Inc. announced that it has commenced a private offering of $1.5 billion aggregate principal amount of senior notes due 2031, subject to market and other conditions.

Mind Medicine Inc., the leading psychedelic pharmaceutical company, has engaged renowned psychedelic assisted therapy expert Dr. Peter Gasser as an advisor to its LSD experiential therapy program Project Lucy.

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the second quarter ended June 30, 2020 and provided a corporate update.

- Dr. Chuck Drake & Dr. Bree Wilky to discuss AGEN1181 & zalifrelimab - new responses - AGEN2373 achieves durable SDs in early Ph1; balstilimab combos to start - Zalifrelimab achieves responses in PD-1 failures (1CR, 3PRs); Ph2 expansion underway - Next-gen CTLA-4, PD-1 & iNKT activating therapy shows curative potential (AACR2020) - Renewably sourced QS-21 shows bio-equivalence; QS-21 enhances antibody titers in SARS-CoV-2 models - Pa

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2020, and provided a business update.

Precigen Triple-Gene, a clinical stage cardiovascular gene therapy company and majority-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced six-month follow-up data from the Phase I trial of INXN-4001 (clinical trial identifier: NCT03409627),

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2020 and provided an update on recent accomplishments and upcoming events.